National Bank of Canada
ESPR

National Bank of Canada’s Esperion Therapeutics ESPR Stock Holding History

National Bank of Canada’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-165
Closed -$610 – 3033
2025
Q4 		$610 Buy
+165
New +$533 ﹤0.01% 2680
2025
Q3 		– Sell
-2,300
Closed -$2.27K – 2958
2025
Q2 		$2.27K Buy
2,300
+900
+64% +$901 ﹤0.01% 2605
2025
Q1 		$2.02K Sell
1,400
-1,050
-43% -$1.94K ﹤0.01% 2506
2024
Q4 		$5.39K Sell
2,450
-6,200
-72% -$14.5K ﹤0.01% 2438
2024
Q3 		$14.3K Sell
8,650
-10,400
-55% -$21K ﹤0.01% 2005
2024
Q2 		$44.2K Buy
19,050
+10,225
+116% +$24.1K ﹤0.01% 1733
2024
Q1 		$19.3K Buy
+8,825
New +$21.4K ﹤0.01% 2037
2023
Q2 		– Sell
-10,446
Closed -$16.6K – 2749
2023
Q1 		$16.6K Sell
10,446
-96
-0.9% -$496 ﹤0.01% 2019
2022
Q4 		$65.7K Sell
10,542
-376
-3% -$2.69K ﹤0.01% 1665
2022
Q3 		$73K Sell
10,918
-177
-2% -$1.22K ﹤0.01% 1596
2022
Q2 		$70K Sell
11,095
-137
-1% -$777 ﹤0.01% 1663
2022
Q1 		$52K Sell
11,232
-1,077
-9% -$4.62K ﹤0.01% 1860
2021
Q4 		$61K Buy
+12,309
New +$98.6K ﹤0.01% 1789

Other funds holding ESPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

National Bank of Canada's ESPR Position: Q1 2026 in Review

National Bank of Canada sold out of Esperion Therapeutics (ESPR) in Q1 2026, closing a stake of 165 shares — an estimated $610 sold.

National Bank of Canada first reported a position in ESPR in Q4 2021 and held it in 13 quarters. The position peaked at $73K in Q3 2022. 205 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • National Bank of Canada reported no remaining Esperion Therapeutics position as of Q1 2026 after selling out during the quarter.
  • National Bank of Canada sold 165 Esperion Therapeutics shares in Q1 2026, an estimated $610.
  • National Bank of Canada first reported a position in Esperion Therapeutics in Q4 2021 and held it in 13 quarters.
  • National Bank of Canada's Esperion Therapeutics position peaked at $73K in Q3 2022.
  • 205 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.